CELCUITY

Celcuity was founded in 2012 by Brian Sullivan and Lance Laing, PhD, to develop a better way to diagnose and treat the cellular abnormalities that drive tumor growth. Our team of drug development scientists, biochemists, molecular biologists, and diagnostics experts are advancing new targeted therapies for cancer using an integrated therapeutic and companion diagnostic strategy that leverages our CELsignia platform... We are a clinical stage biotechnology company that discovers previously undetectable cancer drivers and develops drugs to treat them... With our CELsignia companion diagnostic platform, we are collaborating with leading pharmaceutical companies to evaluate their targeted therapeutics in CELsignia-selected patients.

Also known as: Celcuity, Inc.

Primary location: Minneapolis United States